Lokivetmab

Lokivetmab is a monoclonal antibody used in veterinary medicine for the treatment of canine atopic dermatitis. It is marketed under the trade name Cytopoint by Zoetis, a global animal health company.

Mechanism of Action

Lokivetmab works by targeting and neutralizing interleukin-31 (IL-31), a protein that sends itch signals to the brain. By blocking IL-31, Lokivetmab helps to reduce the itchiness and inflammation associated with atopic dermatitis.

Usage

Lokivetmab is administered by subcutaneous injection and can provide relief from itching for 4 to 8 weeks. The dosage and frequency of administration depend on the dog's weight and the severity of the symptoms.

Side Effects

The most common side effects of Lokivetmab include vomiting, diarrhea, lethargy, and decreased appetite. In rare cases, hypersensitivity reactions may occur.

Regulatory Status

Lokivetmab was approved by the European Medicines Agency (EMA) in 2017 and by the United States Food and Drug Administration (FDA) in 2016.

See Also

• Monoclonal antibodies in veterinary medicine
• Atopic dermatitis in dogs
• Zoetis

References

<references />